1. Home
  2. ARTL vs XRTX Comparison

ARTL vs XRTX Comparison

Compare ARTL & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • XRTX
  • Stock Information
  • Founded
  • ARTL 2011
  • XRTX 2011
  • Country
  • ARTL United States
  • XRTX Canada
  • Employees
  • ARTL N/A
  • XRTX N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • XRTX Pharmaceuticals and Biotechnology
  • Sector
  • ARTL Health Care
  • XRTX Health Care
  • Exchange
  • ARTL Nasdaq
  • XRTX Nasdaq
  • Market Cap
  • ARTL 3.1M
  • XRTX 3.4M
  • IPO Year
  • ARTL N/A
  • XRTX N/A
  • Fundamental
  • Price
  • ARTL $9.35
  • XRTX $0.84
  • Analyst Decision
  • ARTL Strong Buy
  • XRTX
  • Analyst Count
  • ARTL 2
  • XRTX 0
  • Target Price
  • ARTL $24.00
  • XRTX N/A
  • AVG Volume (30 Days)
  • ARTL 124.7K
  • XRTX 105.2K
  • Earning Date
  • ARTL 08-13-2025
  • XRTX 08-15-2025
  • Dividend Yield
  • ARTL N/A
  • XRTX N/A
  • EPS Growth
  • ARTL N/A
  • XRTX N/A
  • EPS
  • ARTL N/A
  • XRTX N/A
  • Revenue
  • ARTL N/A
  • XRTX N/A
  • Revenue This Year
  • ARTL N/A
  • XRTX N/A
  • Revenue Next Year
  • ARTL N/A
  • XRTX N/A
  • P/E Ratio
  • ARTL N/A
  • XRTX N/A
  • Revenue Growth
  • ARTL N/A
  • XRTX N/A
  • 52 Week Low
  • ARTL $4.92
  • XRTX $0.66
  • 52 Week High
  • ARTL $28.60
  • XRTX $2.98
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 41.84
  • XRTX 51.88
  • Support Level
  • ARTL $9.16
  • XRTX $0.70
  • Resistance Level
  • ARTL $10.55
  • XRTX $0.87
  • Average True Range (ATR)
  • ARTL 0.76
  • XRTX 0.07
  • MACD
  • ARTL -0.04
  • XRTX 0.00
  • Stochastic Oscillator
  • ARTL 48.94
  • XRTX 60.87

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: